Syngene International Limited has informed the Exchange regarding 'Receipt of Establishment Inspection Report (EIR) by United States Food & Drug Administration (USFDA)''.
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Syngene International has received the Establishment Inspection Report (EIR) from the USFDA for its GMP manufacturing facilities at Biocon Park, Bengaluru, which were inspected from February 10 to February 20, 2025. The USFDA classified the inspection outcome as Voluntary Action Indicated (VAI), meaning no mandatory regulatory action is required. The USFDA has accepted Syngene's responses and Corrective and Preventive Action (CAPA) plans. The company stated that this outcome will not have any adverse impact on its financials or operations, and it will continue to provide periodic updates on corrective action progress.
Positive/neutral for shareholders — VAI is a favorable outcome indicating the facility remains in good standing with the USFDA, with no operational or financial disruption expected. The clean closure of the inspection supports continued business confidence, particularly for Syngene's contract research and manufacturing services tied to the US market.